-
Pediatric Blood & Cancer Oct 2023
Topics: Child; Humans; Cardiotoxicity; Dexrazoxane; Anthracyclines; Neoplasms; Antibiotics, Antineoplastic; Polyketides; Razoxane; Cardiotonic Agents
PubMed: 37505793
DOI: 10.1002/pbc.30604 -
Current Treatment Options in Oncology Aug 2023As chemotherapy continues to improve the lives of patients with cancer, understanding the effects of these drugs on other organ systems, and the cardiovascular system in... (Review)
Review
As chemotherapy continues to improve the lives of patients with cancer, understanding the effects of these drugs on other organ systems, and the cardiovascular system in particular, has become increasingly important. The effects of chemotherapy on the cardiovascular system are a major determinant of morbidity and mortality in these survivors. Although echocardiography continues to be the most widely used modality for assessing cardiotoxicity, newer imaging modalities and biomarker concentrations may detect subclinical cardiotoxicity earlier. Dexrazoxane continues to be the most effective therapy for preventing anthracycline-induced cardiomyopathy. Neurohormonal modulating drugs have not prevented cardiotoxicity, so their widespread, long-term use for all patients is currently not recommended. Advanced cardiac therapies, including heart transplant, have been successful in cancer survivors with end-stage HF and should be considered for these patients. Research on new targets, especially genetic associations, may produce treatments that help reduce cardiovascular morbidity and mortality.
Topics: Humans; Adolescent; Young Adult; Child; Antineoplastic Agents; Cardiotoxicity; Neoplasms; Heart; Cardiomyopathies; Anthracyclines
PubMed: 37296365
DOI: 10.1007/s11864-023-01100-4